Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif
This article was originally published in The Pink Sheet Daily
Executive Summary
With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.